Flu Shots Changed: All Three Components Updated for Fall 2024

World Health Organization collaborating centers have recommended a complete replacement of all three viral components in Northern Hemisphere influenza vaccines for the 2024–2025 season, reflecting the near-total displacement of previously circulating strains by antigenically distinct variants. The updated trivalent formulation targets two influenza A subtypes — A/H1N1 and A/H3N2 — and one influenza B/Victoria lineage virus, based on year-round surveillance data from the Global Influenza Surveillance and Response System (GISRS) spanning more than 100 countries. Strain changes driven by antigenic drift Influenza viruses undergo continuous antigenic drift — gradual mutations in surface proteins hemagglutinin and neuraminidase that allow the virus to evade existing population immunity. When the antigenic distance between circulating viruses and vaccine strains exceeds a threshold, vaccine effectiveness drops sharply. WHO's February 2024 composition meeting concluded that all three components from the 2023–2024 vaccine no longer matched the dominant circulating strains. The A/H3N2 component, historically associated with more severe seasons and higher hospitalization rates in older adults, has been updated to a clade 2.3.4.4b virus (A/Thailand/8/2022-like) replacing the previous A/Darwin/9/2021-like strain. Clinicians note this subtype often drives earlier epidemic onset. The A/H1N1 component shifts to an A/Victoria/4897/2022-like virus (clade 5a.2a.1), while the B/Victoria component moves to a B/Austria/1359417/2021-like virus (clade V1A.3a.2). The B/Yamagata lineage, absent from global circulation since March 2020, remains excluded from trivalent formulations.